Ascend Gene and Cell Therapies, a manufacturing capacity for any gene and cell therapy developer, completed the acquisition of Freeline Therapeutics, a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies, from Freeline Therapeutics Holdings, a biotechnology company, for $25m. The companies also entered into a transition services agreement that allows Freeline to maintain flexible access to analytical and process development capabilities and dedicated personnel for a period of 18 months following the closing of the transaction.